SMT201400034B - Azetidinl diammidi come inibitori di monoacilglicerolo lipasi - Google Patents

Azetidinl diammidi come inibitori di monoacilglicerolo lipasi

Info

Publication number: SMT201400034B
Authority: SM; San Marino
Prior art keywords: azetidinl; diamonds; lipase inhibitors; monoacylglycerol lipase; monoacylglycerol
Prior art date: 2009-04-22

Application number

SM201400034T

Other languages

English (en)

Inventor

Haiyan Bian

Kristen M Chevalier

Peter J Connolly

Li Lin

Christopher M Flores

Shu-Chen Lin

John Mabus

Mark J Macielag

Mark E Mcdonnell

Philip M Pitis

Sui-Po Zhang

Yue-Mei Zhang

Bin Zhu

Jose Clemente

Original Assignee

Janssen Parmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-22

Filing date

2014-03-20

Publication date

2014-05-07

2014-03-20 Application filed by Janssen Parmaceutica Nv filed Critical Janssen Parmaceutica Nv

2014-05-07 Publication of SMT201400034B publication Critical patent/SMT201400034B/it

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Immunology (AREA)
Oncology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

SM201400034T 2009-04-22 2014-03-20 Azetidinl diammidi come inibitori di monoacilglicerolo lipasi SMT201400034B (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17165809P	2009-04-22	2009-04-22
US17164909P	2009-04-22	2009-04-22
PCT/US2010/032082 WO2010124108A1 (en)	2009-04-22	2010-04-22	Azetidinyl diamides as monoacylglycerol lipase inhibitors

Publications (1)

Publication Number	Publication Date
SMT201400034B true SMT201400034B (it)	2014-05-07

Family

ID=42208680

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM201400034T SMT201400034B (it)	2009-04-22	2014-03-20	Azetidinl diammidi come inibitori di monoacilglicerolo lipasi

Country Status (22)

Country	Link
US (16)	US8445477B2 (it)
EP (8)	EP2421848A1 (it)
JP (8)	JP5733840B2 (it)
KR (8)	KR101705049B1 (it)
CN (8)	CN102803210A (it)
AR (8)	AR076380A1 (it)
AU (9)	AU2010239188B2 (it)
BR (8)	BRPI1013545A2 (it)
CA (8)	CA2759547A1 (it)
DK (1)	DK2421825T3 (it)
ES (2)	ES2455744T3 (it)
HK (2)	HK1170221A1 (it)
HR (1)	HRP20140295T1 (it)
IL (8)	IL215780A (it)
PL (1)	PL2421825T3 (it)
PT (1)	PT2421825E (it)
RS (1)	RS53235B (it)
RU (8)	RU2011147185A (it)
SI (1)	SI2421825T1 (it)
SM (1)	SMT201400034B (it)
TW (8)	TW201116280A (it)
WO (8)	WO2010124082A1 (it)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8079703B2 (en)	2008-07-21	2011-12-20	Novartis Ag	Silicone-containing polymeric materials with hydrolyzable groups
WO2010124082A1 (en) *	2009-04-22	2010-10-28	Janssen Pharmaceutica Nv	Azetidinyl diamides as monoacylglycerol lipase inhibitors
US9082128B2 (en) *	2009-10-19	2015-07-14	Uniloc Luxembourg S.A.	System and method for tracking and scoring user activities
WO2011058766A1 (en) *	2009-11-16	2011-05-19	Raqualia Pharma Inc.	Aryl carboxamide derivatives as ttx-s blockers
EP3002008B8 (en)	2010-03-11	2018-10-24	New York University	Amido compounds as roryt modulators and uses thereof
BR112013005141A2 (pt)	2010-09-03	2016-05-10	Janssen Pharmaceutica Nv	diazetidinil diamida como inibidores de monoacilglicerol lipase
WO2012044613A1 (en) *	2010-09-27	2012-04-05	Janssen Pharmaceutica Nv	Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors
CN102417483A (zh) *	2010-09-27	2012-04-18	中国药科大学	作为parp抑制剂的2-苯基-1h-苯并咪唑-4-甲酸酯衍生物
RU2013123274A (ru)	2010-10-22	2014-11-27	Янссен Фармацевтика Нв	Аминопирролидиназетидиндиамиды как ингибиторы моноацилглицеринлипазы
US8513423B2 (en)	2010-10-22	2013-08-20	Janssen Pharmaceutica, Nv	Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
BR112013009858A2 (pt) *	2010-10-22	2016-07-26	Janssen Pharmaceutica Nv	diamidas de piperidin-4-il-azetidina como inibidores de monoacilglicerol lipase
AU2012208837B2 (en)	2011-01-20	2016-07-28	Merck Sharp & Dohme Corp.	Mineralocorticoid receptor antagonists
WO2012151448A1 (en) *	2011-05-03	2012-11-08	Agios Pharmaceuticals, Inc.	Pyruvate kinase activators for use in therapy
CN103841973A (zh) *	2011-09-30	2014-06-04	詹森药业有限公司	用于治疗代谢疾病和相关失调的单酰甘油脂肪酶抑制剂
US8835417B2 (en)	2011-09-30	2014-09-16	Janssen Pharmaceutica Nv	Crystalline hydrochloride salt of (1-(4-fluorophenyl)-1H-indol-5-yl)-(3-(4-(thiazole-2-carbonyl)piperazin-1-yl)azetidin-1-yl)methanone
KR20140068243A (ko) *	2011-09-30	2014-06-05	얀센 파마슈티카 엔.브이.	대사 질환 및 관련 장애의 치료를 위한 모노아실글리세롤 리파제 억제제
KR101653473B1 (ko)	2012-01-06	2016-09-01	어바이드 테라퓨틱스, 인크.	카르바메이트 화합물 및 그의 제조 및 이용 방법
CN102603485A (zh) *	2012-02-07	2012-07-25	北京颖新泰康国际贸易有限公司	制备2-甲基-3-苯基苯甲醇的方法
TWI562295B (en)	2012-07-31	2016-12-11	Mediatek Inc	Semiconductor package and method for fabricating base for semiconductor package
EP2917207A1 (en)	2012-11-08	2015-09-16	Agios Pharmaceuticals, Inc.	Therapeutic compounds and compositions and their use as pkm2 modulators
US9745319B2 (en)	2013-03-15	2017-08-29	Araxes Pharma Llc	Irreversible covalent inhibitors of the GTPase K-Ras G12C
AU2014239542A1 (en) *	2013-03-15	2015-10-01	Araxes Pharma Llc	Covalent inhibitors of KRas G12C
UY35464A (es)	2013-03-15	2014-10-31	Araxes Pharma Llc	Inhibidores covalentes de kras g12c.
WO2014139144A1 (en)	2013-03-15	2014-09-18	Agios Pharmaceuticals, Inc.	Therapeutic compounds and compositions
WO2014187744A1 (de)	2013-05-23	2014-11-27	Bayer Pharma Aktiengesellschaft	Pharmazeutische zusammensetzung und deren verwendung sowie anwendungsregime dieser pharmazeutischen zusammensetzung zur bedarfsweisen („on-demand") kontrazeption
JO3805B1 (ar)	2013-10-10	2021-01-31	Araxes Pharma Llc	مثبطات كراس جي12سي
JP6229056B2 (ja) *	2013-11-12	2017-11-08	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	神経変性疾患の処置用の神経新生薬としてのピリド［４，３−ｂ］ピラジン−２−カルボキサミド
EP3087067B1 (en)	2013-12-26	2018-10-24	Takeda Pharmaceutical Company Limited	4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
JO3556B1 (ar)	2014-09-18	2020-07-05	Araxes Pharma Llc	علاجات مدمجة لمعالجة السرطان
EP3197450A1 (en) *	2014-09-22	2017-08-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of fibrosis
US10011600B2 (en)	2014-09-25	2018-07-03	Araxes Pharma Llc	Methods and compositions for inhibition of Ras
WO2016049524A1 (en)	2014-09-25	2016-03-31	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
US10106556B2 (en)	2015-03-30	2018-10-23	Takeda Pharmaceutical Company Limited	Heterocyclic compound
CN107849022A (zh)	2015-04-10	2018-03-27	亚瑞克西斯制药公司	取代的喹唑啉化合物和其使用方法
WO2016168540A1 (en)	2015-04-15	2016-10-20	Araxes Pharma Llc	Fused-tricyclic inhibitors of kras and methods of use thereof
IL305843A (en)	2015-07-20	2023-11-01	Genzyme Corp	CSF-1R receptor antagonists
US10144724B2 (en)	2015-07-22	2018-12-04	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
CU20170166A7 (es)	2015-07-31	2018-03-13	Pfizer	Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1, 1, 1-trifluoro-4-hidroxibutan-2-il carbamato como inhibidores de magl
US10858343B2 (en)	2015-09-28	2020-12-08	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
WO2017058768A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
US10875842B2 (en)	2015-09-28	2020-12-29	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
US10882847B2 (en)	2015-09-28	2021-01-05	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
EP3356339A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
EP3356354A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en)	2015-10-19	2017-04-27	Araxes Pharma Llc	Method for screening inhibitors of ras
AU2016355433C1 (en)	2015-11-16	2021-12-16	Araxes Pharma Llc	2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en)	2015-12-09	2017-06-15	Araxes Pharma Llc	Methods for preparation of quinazoline derivatives
AU2017213154B2 (en)	2016-01-27	2023-02-02	Universität Zürich	Use of GABAA receptor modulators for treatment of itch
US10463753B2 (en)	2016-02-19	2019-11-05	Lundbeck La Jolla Research Center, Inc.	Radiolabeled monoacylglycerol lipase occupancy probe
US10822312B2 (en)	2016-03-30	2020-11-03	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use
AU2017245125B2 (en)	2016-03-31	2020-10-22	Takeda Pharmaceutical Company Limited	Heterocyclic compound
JP6832342B2 (ja) *	2016-03-31	2021-02-24	武田薬品工業株式会社	複素環化合物
US10646488B2 (en)	2016-07-13	2020-05-12	Araxes Pharma Llc	Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10280172B2 (en)	2016-09-29	2019-05-07	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
US10377743B2 (en)	2016-10-07	2019-08-13	Araxes Pharma Llc	Inhibitors of RAS and methods of use thereof
JOP20190106A1 (ar) *	2016-11-16	2019-05-09	Lundbeck La Jolla Research Center Inc	مثبطات أحادي أسيل جليسرول ليباز (magl)
BR112019014688A2 (pt)	2017-01-20	2020-02-18	Pfizer Inc.	Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl
KR20190097242A (ko)	2017-01-23	2019-08-20	화이자 인코포레이티드	Magl 억제제로서의 헤테로시클릭 스피로 화합물
WO2018140599A1 (en)	2017-01-26	2018-08-02	Araxes Pharma Llc	Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573967A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	Fused hetero-hetero bicyclic compounds and methods of use thereof
EP3573970A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EA201992409A1 (ru)	2017-05-23	2020-03-23	Лундбекк Ла-Хойя Рисерч Сентер, Инк.	Ингибиторы magl на основе пиразола
WO2018218069A1 (en)	2017-05-25	2018-11-29	Araxes Pharma Llc	Quinazoline derivatives as modulators of mutant kras, hras or nras
US10736897B2 (en)	2017-05-25	2020-08-11	Araxes Pharma Llc	Compounds and methods of use thereof for treatment of cancer
BR112019024674A2 (pt)	2017-05-25	2020-06-16	Araxes Pharma Llc	Inibidores covalentes da kras
MX2020007318A (es)	2017-09-29	2020-08-24	Takeda Pharmaceuticals Co	Compuesto heterociclico.
WO2019178129A1 (en)	2018-03-13	2019-09-19	Shire Human Genetic Therapies, Inc.	Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
EP3790551A4 (en)	2018-05-07	2022-03-09	Mirati Therapeutics, Inc.	KRAS G12C INHIBITORS
US11332453B2 (en)	2018-05-15	2022-05-17	H. Lundbeck A/S	MAGL inhibitors
CN109020890B (zh) *	2018-09-12	2022-02-08	南京大学	一类饱和脂肪环骈吡唑衍生物的制备及其应用
BR112021008741A2 (pt)	2018-11-09	2021-08-10	Vivace Therapeutics, Inc.	compostos bicíclicos
MX2021006312A (es) *	2018-11-28	2021-08-11	H Lundbeck As	Inhibidores de magl para usarse para tratar enfermedades.
EP3908283A4 (en)	2019-01-10	2022-10-12	Mirati Therapeutics, Inc.	KRAS G12C INHIBITORS
WO2020179859A1 (ja)	2019-03-06	2020-09-10	第一三共株式会社	ピロロピラゾール誘導体
AU2020257207A1 (en)	2019-04-16	2021-11-25	Vivace Therapeutics, Inc.	Bicyclic compounds
US11453683B1 (en)	2019-08-29	2022-09-27	Mirati Therapeutics, Inc.	KRas G12D inhibitors
JP2022548696A (ja)	2019-09-18	2022-11-21	武田薬品工業株式会社	血漿カリクレインインヒビター及びその使用
JP2022549601A (ja)	2019-09-18	2022-11-28	武田薬品工業株式会社	ヘテロアリール血漿カリクレインインヒビター
AU2020356455A1 (en)	2019-09-24	2022-04-14	Mirati Therapeutics, Inc.	Combination therapies
EP4076418A4 (en)	2019-12-20	2024-01-24	Mirati Therapeutics Inc	SOS1 INHIBITORS
CN115335043A (zh) *	2020-01-23	2022-11-11	迈欧伏特治疗公司	Pgdh抑制剂以及制备和使用方法
EP3875452A1 (en) *	2020-03-04	2021-09-08	Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis	Monoacylglycerol lipase inhibitors
AU2021240349A1 (en) *	2020-03-26	2022-09-29	Janssen Pharmaceutica Nv	Aminocyclobutanes as monoacylglycerol lipase modulators
EP4267573A1 (en)	2020-12-23	2023-11-01	Genzyme Corporation	Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
KR20220153888A (ko) *	2021-05-12	2022-11-21	에이치케이이노엔 주식회사	신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도
EP4377314A1 (en) *	2021-07-28	2024-06-05	Epirium Bio Inc.	Bicyclic pgdh inhibitors and methods of making and using

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9600235D0 (en) *	1996-01-05	1996-03-06	Pfizer Ltd	Therapeutic agents
WO1998037077A1 (en)	1997-02-24	1998-08-27	Zymogenetics, Inc.	Calcitonin mimetics
WO1999019297A1 (en)	1997-10-15	1999-04-22	Coelacanth Chemical Corporation	Synthesis of azetidine derivatives
WO2000063168A1 (en)	1999-04-16	2000-10-26	Coelacanth Chemical Corporation	Synthesis of azetidine derivatives
US6566356B2 (en)	2000-03-03	2003-05-20	Aventis Pharma S.A.	Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
AR033517A1 (es)	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
FR2829028B1 (fr)	2001-08-29	2004-12-17	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
TW200300757A (en) *	2001-11-16	2003-06-16	Schering Corp	Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
US6995144B2 (en)	2002-03-14	2006-02-07	Eisai Co., Ltd.	Nitrogen containing heterocyclic compounds and medicines containing the same
EP2508204B1 (en)	2002-06-26	2014-09-24	Ono Pharmaceutical Co., Ltd.	Remedies for diseases caused by vascular contraction or dilation
JP4660199B2 (ja) *	2002-12-23	2011-03-30	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
FR2854633B1 (fr) *	2003-05-07	2005-06-24	Sanofi Synthelabo	Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
DE602004013772D1 (de) *	2003-06-10	2008-06-26	Janssen Pharmaceutica Nv	Kombination von opioiden und einem piperazin-derivat für die behandlung von schmerzen
EP1702916A1 (en)	2005-03-18	2006-09-20	Santhera Pharmaceuticals (Schweiz) GmbH	DPP-IV inhibitors
US20100069346A1 (en) *	2005-06-23	2010-03-18	Sara Holmqvist	New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases
EP1966143A2 (en)	2005-12-21	2008-09-10	Schering Corporation	Substituted aniline derivatives useful as histamine h3 antagonists
DE102006016023A1 (de) *	2006-04-05	2007-10-11	Basf Ag	Funktionale Expression von Triacylglycerol-Lipasen
CN101528712B (zh)	2006-08-26	2013-10-30	Abbvie德国有限责任两合公司	取代的苯并咪唑酮衍生物、包含它们的药物以及其用途
FR2915199B1 (fr) *	2007-04-18	2010-01-22	Sanofi Aventis	Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2915198B1 (fr)	2007-04-18	2009-12-18	Sanofi Aventis	Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
FR2915197B1 (fr) *	2007-04-18	2009-06-12	Sanofi Aventis Sa	Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
US9271962B2 (en)	2008-03-17	2016-03-01	Northeastern University	Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
JP5715945B2 (ja)	2008-04-25	2015-05-13	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	モノアシルグリセロールリパーゼ（ｍｇｌｌ）の結晶構造
EP2180048B1 (en)	2008-10-09	2014-12-17	Janssen Pharmaceutica N.V.	Alternative crystal form of monoacylglycerol lipase (MGLL)
US8415341B2 (en)	2009-04-22	2013-04-09	Janssen Pharmaceutica, Nv	Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
AU2010238745A1 (en)	2009-04-22	2011-11-10	Janssen Pharmaceutica Nv	Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor
WO2010124082A1 (en)	2009-04-22	2010-10-28	Janssen Pharmaceutica Nv	Azetidinyl diamides as monoacylglycerol lipase inhibitors
DE102012109699A1 (de)	2012-10-11	2014-04-17	Pavel Abdulkin	Verfahren zum Bereitstellen einer Gold-Nano-Hülle um kleine, magnetische Partikel im Submikrometerbereich und so erhaltene Partikel

2010
- 2010-04-22 WO PCT/US2010/032045 patent/WO2010124082A1/en active Application Filing
- 2010-04-22 US US12/765,048 patent/US8445477B2/en active Active
- 2010-04-22 RU RU2011147185/04A patent/RU2011147185A/ru not_active Application Discontinuation
- 2010-04-22 CN CN2010800287463A patent/CN102803210A/zh active Pending
- 2010-04-22 RU RU2011147181/04A patent/RU2011147181A/ru not_active Application Discontinuation
- 2010-04-22 CN CN2010800287586A patent/CN102459255A/zh active Pending
- 2010-04-22 EP EP10715461A patent/EP2421848A1/en not_active Withdrawn
- 2010-04-22 CA CA2759547A patent/CA2759547A1/en not_active Abandoned
- 2010-04-22 AR ARP100101341A patent/AR076380A1/es not_active Application Discontinuation
- 2010-04-22 KR KR1020117027691A patent/KR101705049B1/ko active IP Right Grant
- 2010-04-22 RU RU2011147230/04A patent/RU2011147230A/ru not_active Application Discontinuation
- 2010-04-22 BR BRPI1013545A patent/BRPI1013545A2/pt not_active IP Right Cessation
- 2010-04-22 TW TW099112751A patent/TW201116280A/zh unknown
- 2010-04-22 JP JP2012507387A patent/JP5733840B2/ja not_active Expired - Fee Related
- 2010-04-22 RU RU2011147207/04A patent/RU2011147207A/ru not_active Application Discontinuation
- 2010-04-22 CA CA2759614A patent/CA2759614C/en not_active Expired - Fee Related
- 2010-04-22 AR ARP100101338A patent/AR076377A1/es not_active Application Discontinuation
- 2010-04-22 KR KR1020117027313A patent/KR20120034615A/ko not_active Application Discontinuation
- 2010-04-22 ES ES10716205.9T patent/ES2455744T3/es active Active
- 2010-04-22 AR ARP100101340A patent/AR076379A1/es not_active Application Discontinuation
- 2010-04-22 DK DK10716205.9T patent/DK2421825T3/da active
- 2010-04-22 EP EP10716672A patent/EP2421856A1/en not_active Withdrawn
- 2010-04-22 CA CA2759505A patent/CA2759505A1/en not_active Abandoned
- 2010-04-22 CN CN2010800287590A patent/CN102459228A/zh active Pending
- 2010-04-22 EP EP10715460A patent/EP2421824A1/en not_active Withdrawn
- 2010-04-22 PT PT107162059T patent/PT2421825E/pt unknown
- 2010-04-22 JP JP2012507392A patent/JP2012524807A/ja not_active Withdrawn
- 2010-04-22 CA CA2759501A patent/CA2759501A1/en not_active Abandoned
- 2010-04-22 EP EP10716205.9A patent/EP2421825B9/en active Active
- 2010-04-22 RU RU2011147236/04A patent/RU2011147236A/ru not_active Application Discontinuation
- 2010-04-22 EP EP10717365A patent/EP2421847A1/en not_active Withdrawn
- 2010-04-22 AR ARP100101342A patent/AR076381A1/es not_active Application Discontinuation
- 2010-04-22 TW TW099112753A patent/TW201103932A/zh unknown
- 2010-04-22 JP JP2012507377A patent/JP2012524800A/ja not_active Withdrawn
- 2010-04-22 WO PCT/US2010/032092 patent/WO2010124116A1/en active Application Filing
- 2010-04-22 AU AU2010239188A patent/AU2010239188B2/en not_active Ceased
- 2010-04-22 TW TW099112746A patent/TW201105654A/zh unknown
- 2010-04-22 RU RU2011147206/04A patent/RU2569298C2/ru not_active IP Right Cessation
- 2010-04-22 AU AU2010238738A patent/AU2010238738A1/en not_active Abandoned
- 2010-04-22 AU AU2010238736A patent/AU2010238736A1/en not_active Abandoned
- 2010-04-22 ES ES10715457.7T patent/ES2538326T3/es active Active
- 2010-04-22 SI SI201030535T patent/SI2421825T1/sl unknown
- 2010-04-22 WO PCT/US2010/032068 patent/WO2010124102A1/en active Application Filing
- 2010-04-22 RU RU2011147200/04A patent/RU2011147200A/ru not_active Application Discontinuation
- 2010-04-22 US US12/765,179 patent/US8450303B2/en active Active
- 2010-04-22 CN CN2010800288396A patent/CN102459240A/zh active Pending
- 2010-04-22 PL PL10716205T patent/PL2421825T3/pl unknown
- 2010-04-22 WO PCT/US2010/032086 patent/WO2010124112A1/en active Application Filing
- 2010-04-22 JP JP2012507382A patent/JP2012524802A/ja not_active Withdrawn
- 2010-04-22 CN CN2010800287478A patent/CN102459230A/zh active Pending
- 2010-04-22 BR BRPI1014281A patent/BRPI1014281A2/pt not_active IP Right Cessation
- 2010-04-22 WO PCT/US2010/032049 patent/WO2010124086A1/en active Application Filing
- 2010-04-22 BR BRPI1015238A patent/BRPI1015238A2/pt not_active IP Right Cessation
- 2010-04-22 US US12/765,103 patent/US8455476B2/en active Active
- 2010-04-22 TW TW099112750A patent/TW201103931A/zh unknown
- 2010-04-22 CA CA2759621A patent/CA2759621C/en not_active Expired - Fee Related
- 2010-04-22 TW TW099112749A patent/TWI465446B/zh not_active IP Right Cessation
- 2010-04-22 AU AU2010239204A patent/AU2010239204A1/en not_active Abandoned
- 2010-04-22 AR ARP100101335A patent/AR076374A1/es not_active Application Discontinuation
- 2010-04-22 RU RU2011147233/04A patent/RU2549547C2/ru not_active IP Right Cessation
- 2010-04-22 CN CN2010800287603A patent/CN102548982A/zh active Pending
- 2010-04-22 BR BRPI1013540-5A patent/BRPI1013540A2/pt not_active IP Right Cessation
- 2010-04-22 KR KR1020117027334A patent/KR20120034617A/ko not_active Application Discontinuation
- 2010-04-22 JP JP2012507390A patent/JP2012524806A/ja not_active Withdrawn
- 2010-04-22 KR KR1020117027341A patent/KR20110137831A/ko not_active Application Discontinuation
- 2010-04-22 CA CA2759604A patent/CA2759604A1/en not_active Abandoned
- 2010-04-22 US US12/765,076 patent/US8367653B2/en active Active
- 2010-04-22 US US12/765,018 patent/US8426401B2/en active Active
- 2010-04-22 AU AU2010238732A patent/AU2010238732B2/en not_active Ceased
- 2010-04-22 WO PCT/US2010/032089 patent/WO2010124114A1/en active Application Filing
- 2010-04-22 EP EP10715456A patent/EP2421860A1/en not_active Withdrawn
- 2010-04-22 AR ARP100101337A patent/AR076376A1/es unknown
- 2010-04-22 BR BRPI1014876A patent/BRPI1014876A2/pt not_active IP Right Cessation
- 2010-04-22 WO PCT/US2010/032095 patent/WO2010124119A1/en active Application Filing
- 2010-04-22 AU AU2010238740A patent/AU2010238740A1/en not_active Abandoned
- 2010-04-22 JP JP2012507378A patent/JP5649644B2/ja not_active Expired - Fee Related
- 2010-04-22 RS RS20140136A patent/RS53235B/en unknown
- 2010-04-22 KR KR1020117027324A patent/KR20120034616A/ko not_active Application Discontinuation
- 2010-04-22 US US12/765,487 patent/US8362001B2/en active Active
- 2010-04-22 CN CN201080028726.6A patent/CN102459166B/zh not_active Expired - Fee Related
- 2010-04-22 AR ARP100101343A patent/AR076382A1/es not_active Application Discontinuation
- 2010-04-22 EP EP10716203A patent/EP2421851A1/en not_active Withdrawn
- 2010-04-22 CN CN201080028749.7A patent/CN102459167B/zh not_active Expired - Fee Related
- 2010-04-22 AU AU2010238743A patent/AU2010238743A1/en not_active Abandoned
- 2010-04-22 KR KR1020117027340A patent/KR20120035146A/ko not_active Application Discontinuation
- 2010-04-22 AU AU2010239184A patent/AU2010239184A1/en not_active Abandoned
- 2010-04-22 CA CA2759697A patent/CA2759697A1/en not_active Abandoned
- 2010-04-22 WO PCT/US2010/032082 patent/WO2010124108A1/en active Application Filing
- 2010-04-22 US US12/765,420 patent/US8362000B2/en active Active
- 2010-04-22 BR BRPI1013538A patent/BRPI1013538A2/pt not_active IP Right Cessation
- 2010-04-22 TW TW099112752A patent/TW201105665A/zh unknown
- 2010-04-22 CA CA2759713A patent/CA2759713A1/en not_active Abandoned
- 2010-04-22 US US12/765,254 patent/US8399454B2/en active Active
- 2010-04-22 KR KR1020117027654A patent/KR101705697B1/ko active IP Right Grant
- 2010-04-22 KR KR1020117027713A patent/KR20120034623A/ko not_active Application Discontinuation
- 2010-04-22 JP JP2012507388A patent/JP2012524804A/ja not_active Withdrawn
- 2010-04-22 EP EP10715457.7A patent/EP2421823B1/en active Active
- 2010-04-22 JP JP2012507389A patent/JP2012524805A/ja not_active Withdrawn
- 2010-04-22 TW TW099112747A patent/TWI483940B/zh not_active IP Right Cessation
- 2010-04-22 TW TW099112748A patent/TW201105655A/zh unknown
- 2010-04-22 BR BRPI1014284A patent/BRPI1014284A2/pt not_active IP Right Cessation
- 2010-04-22 BR BRPI1014885A patent/BRPI1014885A8/pt not_active Application Discontinuation
- 2010-04-22 AR ARP100101339A patent/AR076378A1/es unknown
2011
- 2011-10-23 IL IL215780A patent/IL215780A/en not_active IP Right Cessation
- 2011-10-23 IL IL215773A patent/IL215773A/en not_active IP Right Cessation
- 2011-10-23 IL IL215781A patent/IL215781A0/en unknown
- 2011-10-23 IL IL215787A patent/IL215787A0/en unknown
- 2011-10-23 IL IL215785A patent/IL215785A0/en unknown
- 2011-10-23 IL IL215775A patent/IL215775A0/en unknown
- 2011-10-23 IL IL215786A patent/IL215786A0/en unknown
- 2011-10-23 IL IL215798A patent/IL215798A0/en unknown
2012
- 2012-10-29 HK HK12110778.3A patent/HK1170221A1/xx not_active IP Right Cessation
- 2012-10-30 HK HK12110891.5A patent/HK1170228A1/xx not_active IP Right Cessation
- 2012-12-17 US US13/716,705 patent/US8604017B2/en active Active
- 2012-12-18 US US13/718,056 patent/US8741887B2/en active Active
- 2012-12-18 US US13/718,257 patent/US8623858B2/en active Active
2013
- 2013-01-25 US US13/749,846 patent/US8722658B2/en active Active
- 2013-03-18 US US13/845,982 patent/US8697683B2/en active Active
- 2013-04-22 US US13/867,372 patent/US8962607B2/en active Active
- 2013-04-29 US US13/872,427 patent/US8697684B2/en active Active
- 2013-05-01 US US13/874,835 patent/US8691805B2/en active Active
2014
- 2014-03-20 SM SM201400034T patent/SMT201400034B/it unknown
- 2014-03-27 HR HRP20140295AT patent/HRP20140295T1/hr unknown
2016
- 2016-03-03 AU AU2016201405A patent/AU2016201405A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2010239188B2 (en)	2016-03-31
BRPI1014281A2 (pt)	2019-09-24
US20140243305A1 (en)	2014-08-28
US20130123232A1 (en)	2013-05-16
WO2010124082A1 (en)	2010-10-28
EP2421847A1 (en)	2012-02-29
US20110015171A1 (en)	2011-01-20
US8399454B2 (en)	2013-03-19
KR20120034615A (ko)	2012-04-12
EP2421823A1 (en)	2012-02-29
CA2759614C (en)	2017-09-19
KR20110137834A (ko)	2011-12-23
US20100324011A1 (en)	2010-12-23
JP5733840B2 (ja)	2015-06-10
US8445477B2 (en)	2013-05-21
TW201103918A (en)	2011-02-01
CA2759713A1 (en)	2010-10-28
US20130102585A1 (en)	2013-04-25
RU2011147206A (ru)	2013-05-27
TW201103931A (en)	2011-02-01
AU2010238732B2 (en)	2015-06-11
HRP20140295T1 (hr)	2014-04-25
CA2759621C (en)	2017-09-26
HK1170228A1 (en)	2013-02-22
KR20120034617A (ko)	2012-04-12
EP2421851A1 (en)	2012-02-29
BRPI1013545A2 (pt)	2019-09-24
AR076376A1 (es)	2011-06-08
DK2421825T3 (da)	2014-02-03
US8697683B2 (en)	2014-04-15
US8450303B2 (en)	2013-05-28
IL215773A (en)	2015-05-31
IL215775A0 (en)	2012-01-31
AU2010239184A1 (en)	2011-11-10
KR20120035146A (ko)	2012-04-13
CN102459167A (zh)	2012-05-16
US20130137674A1 (en)	2013-05-30
TW201105655A (en)	2011-02-16
CN102459228A (zh)	2012-05-16
US8691805B2 (en)	2014-04-08
KR20120034623A (ko)	2012-04-12
AU2010238743A1 (en)	2011-11-10
AR076382A1 (es)	2011-06-08
IL215786A0 (en)	2012-01-31
EP2421825B9 (en)	2014-08-20
TWI465446B (zh)	2014-12-21
AR076381A1 (es)	2011-06-08
CN102459230A (zh)	2012-05-16
CN102459240A (zh)	2012-05-16
AU2010238736A1 (en)	2011-11-10
BRPI1014284A2 (pt)	2017-10-10
TW201103930A (en)	2011-02-01
RU2011147233A (ru)	2013-05-27
WO2010124114A1 (en)	2010-10-28
US8623858B2 (en)	2014-01-07
EP2421848A1 (en)	2012-02-29
RS53235B (en)	2014-08-29
US8455476B2 (en)	2013-06-04
JP2012524806A (ja)	2012-10-18
EP2421825A1 (en)	2012-02-29
JP2012524801A (ja)	2012-10-18
AR076377A1 (es)	2011-06-08
US20100324013A1 (en)	2010-12-23
EP2421860A1 (en)	2012-02-29
BRPI1013540A2 (pt)	2020-11-17
TW201105665A (en)	2011-02-16
CA2759621A1 (en)	2010-10-28
AR076380A1 (es)	2011-06-08
US8426401B2 (en)	2013-04-23
EP2421825B1 (en)	2014-01-01
RU2549547C2 (ru)	2015-04-27
AU2016201405A1 (en)	2016-03-24
CA2759547A1 (en)	2010-10-28
IL215780A (en)	2015-05-31
TW201103932A (en)	2011-02-01
WO2010124108A1 (en)	2010-10-28
CA2759501A1 (en)	2010-10-28
EP2421824A1 (en)	2012-02-29
JP2012524802A (ja)	2012-10-18
KR101705697B1 (ko)	2017-02-10
AR076374A1 (es)	2011-06-08
IL215798A0 (en)	2012-01-31
US8962607B2 (en)	2015-02-24
US8741887B2 (en)	2014-06-03
AU2010239204A1 (en)	2011-11-10
US20130217669A1 (en)	2013-08-22
CA2759505A1 (en)	2010-10-28
US8697684B2 (en)	2014-04-15
US20130123233A1 (en)	2013-05-16
RU2011147181A (ru)	2013-05-27
US20110015170A1 (en)	2011-01-20
RU2011147185A (ru)	2013-05-27
WO2010124116A1 (en)	2010-10-28
BRPI1014885A8 (pt)	2018-04-10
US20100331299A1 (en)	2010-12-30
IL215781A0 (en)	2012-01-31
ES2538326T3 (es)	2015-06-19
AU2010238740A1 (en)	2011-11-10
TW201105654A (en)	2011-02-16
US20130237517A1 (en)	2013-09-12
US8362000B2 (en)	2013-01-29
US20100331300A1 (en)	2010-12-30
ES2455744T3 (es)	2014-04-16
WO2010124119A1 (en)	2010-10-28
KR20120034622A (ko)	2012-04-12
US8362001B2 (en)	2013-01-29
CN102548982A (zh)	2012-07-04
IL215773A0 (en)	2012-01-31
US20100324014A1 (en)	2010-12-23
US20130244997A1 (en)	2013-09-19
CN102459166B (zh)	2015-03-25
TWI483940B (zh)	2015-05-11
WO2010124102A1 (en)	2010-10-28
BRPI1013538A2 (pt)	2019-09-24
AU2010238738A1 (en)	2011-11-10
EP2421856A1 (en)	2012-02-29
KR20120034616A (ko)	2012-04-12
CA2759614A1 (en)	2010-10-28
KR101705049B1 (ko)	2017-02-09
JP2012524807A (ja)	2012-10-18
US20100324012A1 (en)	2010-12-23
JP5649644B2 (ja)	2015-01-07
CN102803210A (zh)	2012-11-28
RU2011147207A (ru)	2013-05-27
IL215780A0 (en)	2012-01-31
WO2010124112A1 (en)	2010-10-28
BRPI1015238A2 (pt)	2019-09-24
RU2011147200A (ru)	2013-05-27
CA2759604A1 (en)	2010-10-28
WO2010124086A1 (en)	2010-10-28
JP2012524805A (ja)	2012-10-18
IL215787A0 (en)	2012-01-31
RU2569298C2 (ru)	2015-11-20
BRPI1014885A2 (pt)	2016-04-19
BRPI1014876A2 (pt)	2016-04-12
AR076378A1 (es)	2011-06-08
RU2011147236A (ru)	2013-05-27
US8604017B2 (en)	2013-12-10
US8367653B2 (en)	2013-02-05
KR20110137831A (ko)	2011-12-23
CA2759697A1 (en)	2010-10-28
PL2421825T3 (pl)	2014-06-30
CN102459255A (zh)	2012-05-16
AR076379A1 (es)	2011-06-08
SI2421825T1 (sl)	2014-04-30
IL215785A0 (en)	2012-01-31
JP2012524804A (ja)	2012-10-18
CN102459167B (zh)	2015-04-01
AU2010239188A1 (en)	2011-11-10
EP2421823B1 (en)	2015-01-14
PT2421825E (pt)	2014-03-13
JP2012524800A (ja)	2012-10-18
TW201116280A (en)	2011-05-16
HK1170221A1 (en)	2013-02-22
AU2010238732A1 (en)	2011-11-10
CN102459166A (zh)	2012-05-16
RU2011147230A (ru)	2013-05-27
JP2012524803A (ja)	2012-10-18
US8722658B2 (en)	2014-05-13

Publication	Publication Date	Title
SMT201400034B (it)	2014-05-07	Azetidinl diammidi come inibitori di monoacilglicerolo lipasi
CY2020023I1 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
SMT201600104B (it)	2016-04-29	Inibitore di bromodominio benzodiazepinico
SMT201600311B (it)	2016-11-10	Inibitori di cdk
SMT201600081B (it)	2016-04-29	Inibitore di bromodominio di benzodiazepina
SMT201500271B (it)	2016-01-08	Inibitori di neprilisina
SMT201500043B (it)	2015-05-05	Indazoli ossazolo-sostituiti come inibitori di pi13-chinasi
IL225769A0 (en)	2013-06-27	Piperidine-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
SMT201400116B (it)	2014-11-10	Pirimidinoni come inibitori delle PI13K
CO6781493A2 (es)	2013-10-31	Inhibidores de la faah
CR20120576A (es)	2013-03-04	Inhibidores de pirazolil quinazolina cinasa
BR112012005146A2 (pt)	2018-01-23	fotobiorreator
GB201004179D0 (en)	2010-04-28	Enzyme inhibitors
GB201004178D0 (en)	2010-04-28	Enzyme inhibitors
IL225815A0 (en)	2013-06-27	Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
SMT201500157B (it)	2015-09-07	Pirazolilaminopiridine come inibitori di fak
BRPI0918564A2 (pt)	2015-12-01	inibidores
BR112012005382A2 (pt)	2016-03-29	inibidores de jak
BRPI1011267A2 (pt)	2016-03-22	inibidores de protease
BRPI1009018A2 (pt)	2015-12-01	fotobiorreator
DK2516435T3 (da)	2014-10-13	Inhibitorer af AKT-aktivitet
BRPI0918966A2 (pt)	2015-12-01	inibidores de protease
SMT201500178B (it)	2015-09-07	Inibitori di nf-kb
BRPI0919073A2 (pt)	2016-03-15	inibidores de protease
DK2464271T3 (da)	2013-08-26	Svaber